Vericel Corporation — Q1 2024 Form 10-Q Summary
Business context and reporting period
Vericel is a commercial-stage biopharmaceutical company focused on sports medicine and severe burn care. It markets MACI, Epicel and NexoBrid in the United States and operates as one reportable segment. This unaudited report covers the three months ended March 31, 2024, compared primarily with the three months ended March 31, 2023.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $51.3 million | $41.0 million | 25.0% increase |
| Gross profit | $35.4 million | $26.5 million | 33.3% increase |
| Gross margin | 69.0% | 64.7% | 430 basis-point expansion |
| Operating loss | $5.5 million | $8.2 million | 33.2% improvement |
| Net loss | $3.9 million | $7.5 million | 48.5% improvement |
| Net loss per share | $0.08 | $0.16 | Improved |
| Operating cash flow | $7.2 million | $7.9 million | Decline of $0.7 million |
Revenue by product was $40.2 million for MACI, $10.7 million for Epicel and $0.4 million for NexoBrid. MACI revenue increased 17.5%, Epicel increased 56.2%, and NexoBrid contributed its first full quarter of reported commercial revenue.
Operating expenses were $40.8 million, including $6.4 million of research and development expense and $34.4 million of selling, general and administrative expense. Non-cash stock-based compensation increased to $9.8 million from $8.7 million.
At March 31, 2024, cash and cash equivalents were $62.9 million, restricted cash was $7.8 million, and investments totaled $77.1 million. Total cash, cash equivalents and restricted cash were $70.7 million. Accounts receivable were $49.9 million and inventory was $13.6 million.
There were no outstanding borrowings under the $150.0 million revolving credit facility. The facility had approximately $6.2 million utilized for letters of credit. Operating lease liabilities totaled $92.2 million. Shareholders’ equity was $233.9 million, and accumulated deficit was $407.0 million.
Material changes versus the prior comparable period
- Revenue growth was driven by MACI volume and price growth, higher Epicel volume and the commercial launch of NexoBrid.
- Gross margin expanded due to higher revenue against a largely fixed manufacturing cost structure.
- Research and development expense rose 23.1%, primarily due to higher headcount and increased MACI arthroscopic delivery development costs.
- Selling, general and administrative expense increased 16.7%, primarily because of higher headcount, employee costs and Burlington facility lease expense.
- Interest income increased to $1.8 million from $0.8 million, reflecting higher returns on marketable securities and money market funds.
- Investing cash flow changed to a $25.5 million use from a $2.8 million source, primarily because of $14.0 million of property and equipment purchases and $22.6 million of investment purchases.
- Property and equipment increased to $56.4 million from $41.6 million, mainly reflecting construction in process for the Burlington facility.
Guidance, outlook, risks and unusual items
- Management expects existing cash, investments, product-sale cash flows and available borrowing capacity to support current operations for at least 12 months from issuance of the financial statements. No quantified revenue, earnings or margin guidance was provided in the filing.
- Management anticipates a commercial launch of the MACI arthroscopic delivery program in the third quarter of 2024, subject to FDA review of the prior approval supplement.
- Vericel expects to initiate a MACI ankle clinical trial beginning in 2025. Any potential approval and commercial contribution would be longer term.
- In April 2024, after the quarter ended, the company funded approximately $28.3 million of additional Burlington tenant-improvement costs from cash on hand. The Burlington facility is expected to become the company’s new headquarters and primary manufacturing facility.
- NexoBrid supply depends substantially on MediWound, including manufacturing operations in Israel and certain raw materials sourced from Taiwan. The company reported no current supply disruption but identified the Israel-Hamas conflict and related operational impacts as risks.
- Revenue is subject to estimates for reimbursement, collections, denials and contractual allowances, particularly for MACI. A 50-basis-point change in the estimated uncollectible percentage could have changed Q1 2024 revenue by approximately $0.4 million.
- Potential NexoBrid sales milestone payments of up to $125.0 million and tiered royalties are not recorded as liabilities because the milestones were not yet probable. The first $7.5 million milestone is triggered at annual North American net sales exceeding $75.0 million.
- MACI revenue historically has been seasonally stronger in the fourth quarter, while Epicel revenue is variable because of the low and irregular incidence of severe burns. NexoBrid seasonality remains uncertain because U.S. commercial sales began only in the third quarter of 2023.
- The company reported no material ongoing litigation, no material changes to previously disclosed risk factors, and effective disclosure controls as of March 31, 2024.
Most important facts for investors to verify
- Whether MACI growth and the expanded gross margin are sustained, including the impact of reimbursement estimates and fourth-quarter seasonality.
- Progress and FDA timing for the MACI arthroscopic delivery labeling supplement and the planned 2025 MACI ankle trial.
- NexoBrid adoption, revenue growth, reimbursement, MediWound supply continuity and progress toward sales-based milestone obligations.
- Cash consumption after the approximately $28.3 million Burlington tenant-improvement funding in April 2024 and the pace of additional facility expenditures.
- The company’s path to sustained operating profitability, given ongoing operating losses, $9.8 million of quarterly stock-based compensation and substantial lease obligations.
- Availability and covenant compliance under the $150.0 million revolving credit facility, including the approximately $6.2 million letter-of-credit utilization.